Expanded Access Program:Lenalidomide With or Without Dexamethasone In Previously Treated Subjects With Multiple Myeloma
Status:
Completed
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
Subjects who qualify for participation will receive lenalidomide with or without
dexamethasone in 4 week cycles until disease progression is documented or lenalidomide
becomes commercially available for the indication of multiple myeloma.